Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study
Authors' conclusion
The primary concerns regarding pharmacotherapy for intentional weight loss were efficacy, side effects, lifelong dosing, pharmacokinetics, and cost. Providing access to information about all the pharmacotherapies and the benefits is likely to result in greater penetrance of treatment.
Study context
- Population
- Patients with obesity complications (BMI > 35 kg/m², aged 18–70 years) referred to specialist clinics in NAFLD, DM, hypertension and CKD; 16 males, 17 females10 expressed a view on pharmacotherapy
- Participants
- 33 patients
- Outcome
- Choice of and attitudes towards pharmacotherapy
Methodological detailsparticipatory action study, purposeful sampling, semi-structured interviews, reflective thematic analysis, sub study, Before the interview, participants watched a 60-minute video explaining nutritional therapy, pharmacotherapy and surgery in equipoise
- Participatory action study
- Purposeful sampling
- Semi-structured interviews
- Reflective thematic analysis
- Sub study
- Before the interview, participants watched a 60-minute video explaining nutritional therapy, pharmacotherapy and surgery in equipoise
Main finding
As reported in the abstract
Patients expressing a view on pharmacotherapy
10
30%
Chose pharmacotherapy alone
8
24%
Chose pharmacotherapy combined with nutritional therapy
2
6%
Five themes: attitudes towards pharmacotherapy; attitudes toward size of obesity and its complications; weighing benefits and risks of treatment; knowledge and reassurance of health professionals; costs of drug therapy
5
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →